ArticleOncology letters2025
Timing of thoracic radiotherapy combined with immunotherapy influences pulmonary injury.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Concurrent Stereotactic Radiotherapy and Immune Checkpoint Inhibitors for Multiple Brain Metastases in Non-Small Cell Lung Cancer - A Multi-Center Retrospective Analysis.CNS neuroscience & therapeutics · 2026Article
- [Overview of immune checkpoint inhibitor therapy : What the radiologist should know].Radiologie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to assess the impact of chest radiotherapy combined with immunotherapy at different time points in lung injury. This retrospective study analyzed 35 patients with thoracic tumors (29 lung cancer cases and 6 esophageal cancer cases) who received radiotherapy combined with immunotherapy between January 2021 and December 2023 at at Capital Medical University, affiliated with Beijing Luhe Hospital (Beijing, China), with a median follow-up time of 21 months. Patients were divided into two groups: Group A (sequential, n=17), who received immunotherapy 2 weeks to 6 months before or after radiotherapy, and group B (synchronous, n=18), who received immunotherapy within 2 weeks before or after radiotherapy. Furthermore, the incidence and severity of lung injury, especially pneumonitis, were also compared. Moreover, risk factors for lung injury, as well as 3-year overall survival (OS) rates for stage III and IV lung cancer, were evaluated. There were no significant differences in tumor location, stage, age, tumor type, Eastern Cooperative Oncology Group score or sex between groups. The proportion of PD-1 in group A was higher, while the proportion of PD-L1 was lower, compared with that in group B. Furthermore, radiotherapy techniques and dosimetric parameters were also similar. Moreover, there were no significant differences in onset time between esophagitis, anemia or pneumonitis between the two groups. However, incidence of grade 3 or higher pneumonitis was 0.0% in the sequential group and 23.5% in the synchronous group, which was significantly different. Univariate analysis identified lung mean dose and the percentage volume receiving ≥30 Gy (V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.